id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-P-0259-0003,FDA,FDA-2005-P-0259,Request for Comment on the Status of Pyridoxamine,Notice,Notice of Action Taken,2005-11-22T05:00:00Z,2005,11,2005-11-18T05:00:00Z,2005-12-20T04:59:59Z,2025-03-29T18:56:22Z,,0,0,09000064804444e1
FDA-2005-P-0259-0001,FDA,FDA-2005-P-0259,See FDA-2005-P-0259-0002,Supporting & Related Material,ACK-Acknowledgement Letter (Supporting and Related Material),2005-08-01T04:00:00Z,2005,8,,,2009-01-22T23:44:34Z,,0,0,09000064804444d4
FDA-2005-P-0259-0002,FDA,FDA-2005-P-0259,"Acknowledgement Letter from FDA DDM to BioStratum, Inc.",Other,Acknowledgement Letter/Receipt,2005-08-01T04:00:00Z,2005,8,,,2025-03-24T17:24:32Z,,0,0,09000064804444d7